SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults
Phase 1
Completed
- Conditions
- Smallpox
- Interventions
- Biological: ACAM3000 MVA Vaccine
- First Posted Date
- 2004-03-17
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 110
- Registration Number
- NCT00079820
- Locations
- 🇺🇸
PRA International, Lenexa, Kansas, United States
🇺🇸University of Kentucky Medical Center, Lexington, Kentucky, United States
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
Phase 2
Terminated
- Conditions
- Smallpox
- Interventions
- Biological: ACAM1000
- First Posted Date
- 2003-01-31
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 274
- Registration Number
- NCT00053508
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Mayo Vaccine Research Group, Rochester, Minnesota, United States
🇺🇸Radiant Research, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath